CRISPR Therapeutics recently drew attention as updates highlighted progress in its gene-editing pipeline, including early-stage studies of CTX310, an in vivo therapy designed to lower LDL cholesterol ...
Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...
The problem, Zaaijer explained, is that algorithms used in precision medicine models overwhelming are built on DNA with ...
The genetically engineered food is also protein packed and sustainable, say scientists. Chinese researchers used gene-editing ...
As global temperatures rise, Cold Spring Harbor Laboratory (CSHL) scientists work to grow stronger, more resilient crops. Yet ...
For years, Yale researchers David Breslow and Mustafa Khokha have worked together with a similar challenge in their ...
Los Angeles wildfires, a CRISPR milestone, and a de-extinction controversy are among 2025’s notable events captured in photos ...
A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same ...
The outlook for dementia care is changing fast. UC experts explain what that means for patients and families, and what it ...
This year has seen the approval of several first-in-class therapies for HAE, but in a fragmented space, experts question ...
Explore Intellia Therapeutics, Inc.'s outlook after Phase 3 trial concerns. See how FDA decisions may impact CRISPR therapy ...
The first-ever oat pangenome and pantranscriptome could help scientists breed oats that are more resilient, nutritious and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback